相关实验视频

Updated: May 4, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

GZ17-6.02与卡博普拉丁和埃托波西德相互作用,杀死神经母细胞瘤细胞

Michael R Booth¹, Laurence Booth¹, Jane L Roberts¹

¹Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, Virginia.

Anti-cancer drugs

|March 11, 2025

概括

GZ17-6.02及其修饰形式602NR通过激活自和死亡受体通路来杀死MYCN神经母细胞瘤细胞. 将这些药物与化疗相结合,可以增强细胞杀死,从而提供新的治疗策略.

科学领域:

在瘤学瘤学.
细胞生物学细胞生物学
药理学药理学是指药理学的学科.

背景情况:

神经母细胞瘤 (NB) 是一种儿童癌症,通常过度表达MYCN基因.
针对MYCN过度表达NB细胞的GZ17-6.02的抗癌潜力,一种黄素,哈米因和异黄素的组合,在很大程度上尚未被探索.
了解GZ17-6.02的分子机制,单独和标准化疗,对于治疗的发展至关重要.

研究的目的:

为了研究GZ17-6.02和修改后的比率 (602NR) 对MYCN过度表达神经母细胞的抗癌作用.
阐明细胞通路,包括自和死亡受体信号传递,涉及GZ17-6.02和602NR的抗瘤活性.
评估GZ17-6.02/602NR与埃托波或碳金结合的协同效应.

主要方法:

细胞内免疫阻塞,蓝排除试验,等离子体/siRNA转染.
使用LC3-GFP-RFP表达等离子体对自的评估.
分析关键信号通路,包括ATM,AMPK,mTOR,ER压力和死亡受体.

主要成果:

GZ17-6.02和602NR激活了亲自和亲亡信号蛋白,同时禁用了生存途径.
这两种药物都增强了自细胞形成和自流量,其效果由乙化物或碳白金增强.
与GZ17-6.02相比,602NR表现出增强的自细胞形成,其抗瘤作用取决于ATM,AMPK,Beclin1,ATG5和CD95信号传递.

结论:

GZ17-6.02和602NR对MYCN过度表达细胞表现出强大的抗神经母细胞瘤活性.
抗瘤效应通过诱导自和激活死亡受体通路来调节.
使用GZ17-6.02/602NR和标准化疗剂的联合治疗为神经母细胞瘤治疗提供了一个有前途的策略.

关键词:

在GZ17-6.02中,GZ17-6.02中,GZ17-6.02中自自是自的过程.卡博普拉丁是碳酸盐中的一种.细胞内膜网膜的压力应激这里是etoposide的位置.

更多相关视频

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

Published on: February 7, 2025

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...